Interpace Biosciences, Inc. (IDXG)
1.523
-0.09
(-5.42%)
USD |
OTCM |
Aug 21, 16:00
Interpace Biosciences Enterprise Value : 40.47M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 40.47M |
| August 20, 2026 | 42.88M |
| August 19, 2026 | 41.78M |
| August 18, 2026 | 42.61M |
| August 17, 2026 | 45.38M |
| August 14, 2026 | 44.27M |
| August 13, 2026 | 44.55M |
| August 12, 2026 | 44.55M |
| August 11, 2026 | 44.52M |
| August 10, 2026 | 45.38M |
| August 07, 2026 | 42.88M |
| August 06, 2026 | 43.72M |
| August 05, 2026 | 39.77M |
| August 04, 2026 | 43.44M |
| August 03, 2026 | 42.33M |
| July 31, 2026 | 40.31M |
| July 30, 2026 | 38.18M |
| July 29, 2026 | 41.27M |
| July 28, 2026 | 41.29M |
| July 27, 2026 | 41.07M |
| July 24, 2026 | 38.73M |
| July 23, 2026 | 38.45M |
| July 22, 2026 | 40.11M |
| July 21, 2026 | 39.96M |
| July 20, 2026 | 39.56M |
| Date | Value |
|---|---|
| July 17, 2026 | 40.53M |
| July 16, 2026 | 41.22M |
| July 15, 2026 | 43.16M |
| July 14, 2026 | 43.16M |
| July 13, 2026 | 39.84M |
| July 10, 2026 | 43.72M |
| July 09, 2026 | 43.66M |
| July 08, 2026 | 43.30M |
| July 07, 2026 | 43.85M |
| July 06, 2026 | 43.99M |
| July 02, 2026 | 43.44M |
| July 01, 2026 | 42.88M |
| June 30, 2026 | 43.44M |
| June 29, 2026 | 44.97M |
| June 26, 2026 | 44.14M |
| June 25, 2026 | 43.86M |
| June 24, 2026 | 45.52M |
| June 23, 2026 | 44.97M |
| June 22, 2026 | 43.59M |
| June 18, 2026 | 44.61M |
| June 17, 2026 | 44.00M |
| June 16, 2026 | 41.92M |
| June 15, 2026 | 42.06M |
| June 12, 2026 | 42.75M |
| June 11, 2026 | 44.14M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Exlites Holdings International, Inc. | 15.42M |
| Xcelerate, Inc. | 5.997M |
| Vivos Therapeutics, Inc. | 15.98M |
| Hinge Health, Inc. | 6.708B |
| PD-Rx Pharmaceuticals, Inc. | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.266M |
| Revenue (Quarterly) | 9.131M |
| Total Expenses (Quarterly) | 8.865M |
| EPS Diluted (Quarterly) | 0.0057 |
| Gross Profit Margin (Quarterly) | 61.91% |
| Profit Margin (Quarterly) | 2.91% |
| Earnings Yield | 57.95% |
| Operating Earnings Yield | 9.87% |
| Normalized Earnings Yield | 57.75 |